QUEENSBURY, N.Y., December 31, 2025--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and ...
Serious adverse events occurred in 51.2 and 21.9% of patients receiving melphalan/hepatic delivery system and BAC, respectively. HealthDay News — For patients with unresectable metastatic uveal ...
Results show that percutaneous hepatic perfusion with CHEMOSAT® is an effective and safe treatment option for patients with advanced cholangiocarcinoma and has the potential to prolong life in ...
NEW YORK, Feb. 22, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today ...
Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma Delcath Systems, Inc.
Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announced the publication of results from subgroup analyses of the phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results